Flunitrazepam

Flunitrazepam enhances GABA-A-mediated inhibition of brainstem respiratory centers. In patients with obstructive sleep apnea, existing airway compromise is compounded by drug-induced reduction in respiratory drive and upper airway muscle tone, substantially increasing the risk of prolonged apnea and hypoxia.

Flunitrazepam produces dose-dependent muscle relaxation through potentiation of GABA-A receptors on spinal cord interneurons. In myasthenia gravis, where neuromuscular transmission is already impaired by autoimmune destruction of acetylcholine receptors, additional muscle relaxation may precipitate respiratory failure or severe functional disability.

Flunitrazepam ranks among the highest-abuse-potential benzodiazepines. In an Israeli methadone maintenance population, 92.9% of benzodiazepine abusers selected flunitrazepam as their primary agent (Gelkopf et al. 1999). Controlled studies demonstrate a distinct euphorigenic window at medium doses. Individuals with a history of substance use disorder face substantially elevated risk of dependence and compulsive use.

Flunitrazepam is 95.8% protein-bound to albumin. In severe hepatic impairment, reduced albumin synthesis increases the unbound (active) fraction, effectively lowering therapeutic and toxic thresholds. Although single-dose PK parameters did not differ significantly in compensated cirrhosis (Drouet-Coassolo et al. 1990), decompensated liver disease with hypoalbuminemia is expected to meaningfully alter exposure. Dose reduction and careful monitoring are required.

Benzodiazepines as a class carry teratogenic risk, including associations with cleft palate and other congenital malformations when used in the first trimester. Neonatal withdrawal syndrome (floppy infant syndrome, respiratory depression, feeding difficulties) is documented following third-trimester exposure. No flunitrazepam-specific human teratogenicity data were retrieved, but the class-level risk and mechanism of action support absolute contraindication.

The combination of flunitrazepam with opioids — particularly buprenorphine — has caused multiple documented deaths in France. The interaction is purely pharmacodynamic: concurrent GABAergic and opioid-mediated respiratory depression overwhelms buprenorphine's partial agonist ceiling effect. Crucially, this combined respiratory depression is not reversed by naloxone due to buprenorphine's high mu-receptor affinity and slow dissociation. All opioids combined with flunitrazepam pose similar synergistic respiratory depression risk.

Ethanol co-ingestion substantially reduces the lethal flunitrazepam threshold. In the Australian fatal case series (Drummer et al. 1993), deaths in the ethanol-positive group occurred at postmortem metabolite concentrations roughly one-third of those in the flunitrazepam-only group. Both agents independently depress CNS function via distinct but convergent GABAergic mechanisms, producing additive-to-synergistic respiratory depression.